Drug
Therapeutic Tumor Infiltrating Lymphocytes
CI-DRUG-00000589Explore in graph →NCIt C28699 CIViC
Regulatory
Approvals (0)
Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.
Data not yet available
No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.
What CancerIndex knows
Derived
Development pipeline
Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.
| Scope | Stage | Max phase | Active | Recruiting | Phase 3 | Trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| All cancers | Phase2 | Phase 2 | 16 | 11 | 0 | 50 | 0 | — | — | 1993-07 |
| Malignant Breast Neoplasm | Phase2 | Phase 2 | 2 | 2 | 0 | 5 | 0 | — | — | 1996-02 |
| Malignant Gastric Neoplasm | Phase2 | Phase 2 | 2 | 1 | 0 | 3 | 0 | — | — | Dec 3, 2019 |
| Malignant Lung Neoplasm | Phase2 | Phase 2 | 2 | 2 | 0 | 4 | 0 | — | — | 1996-02 |
| Cutaneous Melanoma | Phase2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — |
Curated evidence
Clinical evidence (2)
CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 27959684
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| HLA-C COPY-NEUTRAL LOSS OF HETEROZYGOSITY1 | ||||||||
| Therapeutic Tumor Infiltrating Lymphocytes | ||||||||
Clinical trials
Trials with this intervention (50)
Most recently updated first, 50 per page.
clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Dataset
- ClinicalTrials.gov API v2 studies
- Retrieved
- Sep 17, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05681780 | Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC | recruiting | Phase 1 | 20 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT04943913 | Study of GC101 TIL in Brain Glioma (Soochow2) | recruiting | Early Phase 1 |